Answers are grounded in this paper and cite their sources.
Even though the guidelines on irritable bowel syndrome (IBS) are similar worldwide, there are differences between countries that can influence management. Our aim was to evaluate the heterogeneity in IBS management in Latin America. An internet survey was applied to 97 gastroenterologists, specialists in disorders of gut-brain interaction (DGBI), from 14 Latin American countries, and included 111 questions: 23 on diagnosis and 88 on treatment. An exploratory, descriptive, observational analysis was carried out on general qualitative data, by IBS subtype and by country. Diagnostic data: 98% of those surveyed utilize the Rome IV criteria; 100% order laboratory tests when there are alarm symptoms; 90% order colonoscopy in patients over 50 years of age; 73% order abdominopelvic CT; 66% order breath tests for SIBO; and 96% order anorectal manometry in IBS-C with symptoms of a defecation disorder. Treatment data: antispasmodics are the most widely prescribed drugs, with differences according to IBS subtype and local availability; 83% indicate a low FODMAP diet; in IBS-D and abdominal distension, more than 90% prescribe rifaximin and/or probiotics, and 81%, cholestyramine; in IBS-C, the most widely prescribed treatments are polyethylene glycol, psyllium, prucalopride, and linaclotide; up to 94% indicate neuromodulators as second-line treatment; and 99% consider indicating psychotherapy in cases of depression. Even though most of the specialists diagnose and treat IBS in accordance with guidelines, there are differences regarding local availability, and abdominopelvic CT appears to be overused. Knowing how general practitioners and internists manage this entity would be useful for establishing practical guidelines on the diagnosis and treatment of IBS that are adjusted by country. Aunque las guías de síndrome de intestino irritable (SII) son similares globalmente, existen diferencias entre países que pueden influir en el manejo. Evaluar la heterogeneidad en el manejo del SII en Latinoamérica. Encuesta por internet a 97 gastroenterólogos expertos en trastornos de interacción intestino cerebro (TIIC) de 14 países, incluyendo 111 preguntas: 23 de diagnóstico y 88 de tratamiento. Análisis observacional descriptivo de exploración de datos de variables cualitativas generales, según subtipo de SII, y por países. Diagnóstico; 98% usa criterios de Roma IV. Todos solicitan pruebas de laboratorio ante signos de alarma y 90% solicita colonoscopia en mayores de 50 años. 73% ordena TAC abdominopélvica, 66% pruebas de aliento para SIBO, y 96% manometría anorrectal en SII-E con síntomas de trastorno evacuatorio. Tratamiento; los antiespasmódicos son los más recetados con diferencias de acuerdo con subtipo y disponibilidad local. En cuanto a dieta, 83% indica dieta baja en FODMAPs. En SII-D y distensión abdominal, más de 90% utiliza rifaximina y/o probióticos, y 81% colestiramina. En SII-E los tratamientos más recetados son polietilenglicol, psyllium, prucaloprida y linaclotida. Hasta 94% indica neuromoduladores como tratamiento de segunda línea, y 99% considera psicoterapia ante depresión. Aunque la mayoría de los expertos diagnostica y trata el SII conforme a guías, existen diferencias de acuerdo con la disponibilidad local y parece abusarse de estudios como TAC abdominopélvica. Sería útil conocer el manejo de médicos generales e internistas y establecer guías prácticas para diagnóstico y tratamiento ajustadas por países.
No takes yet. Share an insight, caveat, or question.
Hanna-Jairala et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: